Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753739 · ClinicalTrials.gov registry record · Phase 2
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 617
- Enrollment target
NCT01753739: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT01753739 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 617 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (364% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753739, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 617 participants
- Enrollment target
Study Summary
This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to Mountain Cedar pollen for at least 2 years prior to the study.
Primary Outcome
Total nasal symptom score (TNSS) was the summed scores for nasal pruritus \[itching\], rhinorrhea \[runny nose\], nasal congestion, and sneezing. Individual nasal symptoms were each rated on a 4-point scale from 0-3 (0=Absent, 1=Mild, 2=Moderate, 3=Severe), with no half-unit assessments. TNSS was the sum score of 4 nasal symptoms with a minimum score of 0 units and a maximum score of 12 units, with higher score corresponding to increased nasal allergy symptoms. Morning and evening scores were av
Interventions
- DRUG Placebo
- DRUG Bepotastine besilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01753739 record still lists
NCT01753739 is an interventional study that assigns participants to a tested intervention. The registered 617 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (364% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01753739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01753739 about?
NCT01753739 is a clinical study titled "Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)". This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to Mountain Cedar pollen f...
What is the current status of trial NCT01753739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 617 participants. The study started on 2013-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01753739?
The interventions under investigation include: Placebo (DRUG), Bepotastine besilate (DRUG).
Who is sponsoring clinical trial NCT01753739?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01753739's enrollment target sits among peer trials
617 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia